Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 3/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL6964761 | 0.96 | PLAU (0.64) | PLAUALDH1A1LMNASMN1; SMN2MAPK1 | |
| Bicarbonate SCHEMBL6969353 | 0.95 | PLAU (0.63) | PLAUALDH1A1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL6433537 | 0.89 | PLAU (0.56) | PLAUALDH1A1PLGPLAT | |
| SCHEMBL7373055 | 0.89 | PLAU (0.56) | PLAUALDH1A1PLGPLAT | |
| SCHEMBL6433534 | 0.89 | PLAU (0.56) | PLAUALDH1A1PLGPLAT | |
| Hydrochloric Acid SCHEMBL6434303 | 0.88 | PLAU (0.55) | PLAUALDH1A1PLGPLAT | |
| Hydrochloric Acid SCHEMBL6433796 | 0.88 | PLAU (0.55) | PLAUALDH1A1PLGPLAT | |
| Hydrochloric Acid SCHEMBL6433802 | 0.88 | PLAU (0.55) | PLAUALDH1A1PLGPLAT | |
| SCHEMBL7378283 | 0.85 | PLAU (0.52) | PLAUPLGPLAT | |
| SCHEMBL6435153 | 0.85 | PLAU (0.52) | PLAUPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023268-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | claimed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | claimed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | claimed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | claimed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1023268-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885ALDH1A1 2641/4885LMNA 1451/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885ALDH1A1 2641/4885LMNA 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.